APP and Alzheimer disease: Furthermore, we used SP600125 (JNK3 inhibitor, 30 mg/kg, i.p) to inject APP/PS1 mice with or without PBM treatment for 30 days to illustrate whether PBM alleviates multiple pathological features associated with AD models by regulating JNK3.